Clinical trials: Aspirin
Bioequivalence
Pharmacokinetic and Pharmacodynamic Assessment of a Novel, Pharmaceutical Lipid-Aspirin Complex
Prospective, Randomized, Crossover, Bioequivalence study
- Trial name
- NCT04008979
- Testing
- Aspirin
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- PLx Pharma
Healthy
Pharmacodynamic Study of Cilostazol in Healthy Volunteers
The primary objective of this study is to investigate the effects of Cilostazol, Acetylsalycylic acid and Clopidogrel alone as well as combinations of Cilostazol/Acetylsalicylic acid and Cilostazol/ Clopidogrel on ex-vivo…
- Trial name
- CiloMecT (NCT02554721)
- Testing
- Cilostazol, Acetylsalicylic acid, Clopidogrel
- Where
- Germany
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Coronary Artery Disease
EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events
EDUCATE is a prospective, multi-center study designed to collect real-world safety and clinical outcomes in subjects receiving one or more Endeavor Zotarolimus-Eluting Stents and either clopidogrel and aspirin or prasugrel and…
- Trial name
- EDUCATE (NCT01069003)
- Testing
- Thienopyridine Therapy, Surveillance Arm
- Where
- United States
- Volunteers
- 2,272 people
- Sponsor
- Medtronic Vascular
Type 2 Diabetes Mellitus
Efficacy and Safety of Dorner Tablets and Aspirin for Prevention of Arteriosclerosis Progress in Type 2 Diabetes Mellitus Patients
The objective was to evaluate the efficacy and safety of combination of beraprost and aspirin for prevention of arteriosclerosis progress in type 2 diabetes mellitus patients.
- Trial name
- NCT02786979
- Testing
- Beraprost, Aspirin
- Where
- 6 sites in China
- Volunteers
- 190 people
- Sponsor
- Astellas Pharma Inc
Peripheral Arterial Disease
Safety and Efficacy Study of a New Intermittent Pneumatic Compression Device to Treat Patients With Peripheral Arterial Disease (PAD) Stage II
The purpose of this study is to evaluate the safety and efficacy of new intermittent pneumatic compression device on initial claudication distance in patients with Peripheral Arterial Disease stage II
- Trial name
- NCT00762086
- Testing
- AngioPress Intermittent pneumatic compression (IPC) Device, Medications and Standard walking exercises
- Where
- 4 sites in Germany, Israel
- Volunteers
- 67 people
- Sponsor
- Mego Afek Ltd.
Stroke
COMbination of Clopidogrel and Aspirin for Prevention of Early REcurrence in Acute Atherothrombotic Stroke
Primary objective: Comparison of efficacy of the combination therapy (clopidogrel plus aspirin) and the aspirin alone (main comparison) to prevent any recurrent ischemic lesion .
- Trial name
- COMPRESS (NCT00814268)
- Testing
- Clopidogrel, Aspirin
- Where
- South Korea
- Volunteers
- 358 people
- Sponsor
- Sanofi
Polycythemia Vera, Myeloproliferative Neoplasm
Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera
This is a randomized, open-label, multicenter, two-arm study to assess the efficacy and safety of ropeginterferon alfa-2b for patients with PV.
- Trial name
- PV (NCT06290765)
- Testing
- Ropeginterferon alfa-2b, Phlebotomy and aspirin
- Sponsor
- PharmaEssentia
Drug Drug Interaction
Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects
This is a randomized, open-label study to evaluate the safety/tolerability and PK/PD drug-drug interactions between DWP14012 and aspirin when administered in combination.
- Trial name
- NCT05304845
- Testing
- DWP14012, Aspirin
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Healthy
Drug-drug Interaction Study of Aggrenox and Omeprazole in Normal Volunteers
The objective of the current study is to investigate if a drug-drug interaction occurs with the administration of omeprazole 80 mg q.d.
- Trial name
- NCT01303445
- Testing
- Aggrenox alone, Aggrenox and omeprazole, Omeprazole alone
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Prevention
Comparative Efficacy & Safety Study of D961H Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With Low-dose Aspirin
To assess the efficacy of D961H 20 mg once daily (q.d.) versus placebo in continuous treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily Low-dose aspirin therapy by evaluating time from…
- Trial name
- NCT01069939
- Testing
- Esomeprazole
- Where
- 46 sites in Japan, South Korea and 1 more
- Volunteers
- 427 people
- Sponsor
- AstraZeneca
Effect of Food, Pharmacokinetics
Food Interaction Study To Assess the Effect of Food on the Pharmacokinetics of Esomeprazole 20 mg/Acetylsalicylic Acid 81 mg
The purpose of the study is to investigate the effects of food, in comparison to fasting conditions, on the extent and rate of absorption of acetylsalicylic acid (ASA) and esomeprazole.
- Trial name
- NCT01163630
- Testing
- esomeprazole/ASA Fixed Dose Combination (FDC)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Coronary Artery Disease
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM (NCT00823212)
- Testing
- PROMUS Coronary Stent System, PROMUS Element Coronary Stent System, Aspirin
- Where
- 133 sites in United States, Australia and 15 more
- Volunteers
- 1,530 people
- Sponsor
- Boston Scientific Corporation
Diabetic Peripheral Angiopathy
A Study to Compare the Effects of Improving the Carotid Artery Intima Media Thickness and Changing Lipid Levels by Cilostazol/Ginkgo Leaf Extract and Aspirin in Diabetic Peripheral Angiopathy.
This study is to compare and evaluate the effect of improving the carotid IMT and lipid level of the Cilostazol/Ginkgo leaf extract group with the aspirin administrated group in patients with diabetic peripheral angiopathy.
- Trial name
- NCT05906199
- Testing
- Renexin CR 200/160mg, Aspirin 100mg
- Where
- 2 sites in South Korea
- Volunteers
- 105 people
- Sponsor
- SK Chemicals Co., Ltd.
Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack)
Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
This study aims to gather information to what extent patients follow the treatment regimen of low-dose aspirin for primary and secondary prevention of diseases of the heart and blood vessels.
- Conditions
- Myocardial Infarction, Stroke (Including Ischaemic Stroke and Transient Ischaemic Attack), Unstable Angina, Angina
- Trial name
- PALACE (NCT04097912)
- Testing
- Acetylsalicylic Acid (Aspirin, BAYE4465)
- Where
- 2 sites in Germany, United Kingdom
- Volunteers
- 99,999 people
- Sponsor
- Bayer
Peripheral Artery Disease
Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
The purpose of study was to test whether rivaroxaban added to standard of care treatment, when compared to placebo, had the potential to reduce the incidence of the clinical events related to the clots and complications of the…
- Trial name
- VOYAGER PAD (NCT02504216)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 532 sites in United States, Argentina and 32 more
- Volunteers
- 6,564 people
- Sponsor
- Bayer
Stroke, Acute, Neurological Impairment
A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke
The purpose of this study is to evaluate the effectiveness of Tanakan® 240mg in association with Acetylsalicylic acid (325mg/day) in the recovery of neurological impairment following ischemic stroke.
- Trial name
- NCT00276380
- Testing
- EGb761, Acetylsalicylic acid
- Where
- 10 sites in Czechia, Poland and 2 more
- Volunteers
- 204 people
- Sponsor
- Ipsen
Platelet Inhibition
A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin
The primary hypothesis of this study is that concomitant multiple-dose administration of PN 400 does not interfere with the platelet inhibitory effects of enteric-coated low-dose aspirin (81 mg), as measured by serum thromboxane…
- Trial name
- NCT01094483
- Testing
- PN400, ASA
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
To Compare the Gastroprotective Effects and Pharmacokinetic Profile of PA Versus Enteric-Coated Aspirin
Primary: To compare the gastroprotective effects of a once-daily dose of PA 325 combination tablet combining 325 mg pH sensitive aspirin and 20 mg immediate release omeprazole versus a once-daily dose of 325 mg enteric coated…
- Trial name
- NCT00442052
- Testing
- aspirin, omeprazole
- Where
- 2 sites in United States, Canada
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- POZEN
Patients Taking Low-dose Aspirin
The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients
The purpose of this study is to research the safety and efficacy of Albis® for the prevention of aspirin-induced gastrointestinal ulcers in patients taking low-dose aspirin.
- Trial name
- AL-PA (NCT01397240)
- Testing
- Albis Tab
- Where
- South Korea
- Volunteers
- 80 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Fibrillation, Atrial, Atrial Fibrillation
Use Of SB424323 With Aspirin In Non-Valvular Atrial Fibrillation In Patients At A Low Or Intermediate Risk For Stroke
This study will allow determination of the pharmacokinetic and pharmacodynamics of SB424323 in a relevant population. The data from this study will be used along with other data to aid in choosing the most appropriate dose for…
- Trial name
- NCT00240643
- Testing
- SB424323
- Where
- 116 sites in United States, Argentina and 23 more
- Volunteers
- 640 people
- Sponsor
- GlaxoSmithKline